What did Sheridan Capital pay for TarryTown ExpoCare Pharmacy?

Sheridan Capital acquired TarryTown ExpoCare Pharmacy for $160.0M in 2020 (11.4x EBITDA). Target EBITDA was approximately $14.0M.

What does TarryTown ExpoCare Pharmacy do?

TarryTown ExpoCare Pharmacy is a pharmacy business.

What multiple did Sheridan Capital pay for TarryTown ExpoCare Pharmacy?

11.4x EBITDA, based on disclosed deal value of $160.0M and disclosed financials.

M&A TRANSACTION · 2020

TarryTown ExpoCare Pharmacy acquired by Sheridan Capital

$160.0M· 11.4x EBITDA

Target

TarryTown ExpoCare Pharmacy

Acquirer

Sheridan Capital

Disclosed financials at time of acquisition

Revenue

—

EBITDA

$14.0M

Deal Value

$160.0M

EV/EBITDA

11.4x

Context

This $160.0M acquisition of TarryTown ExpoCare Pharmacy by Sheridan Capital sits in the pharmacy sub-vertical. The 11.4x EBITDA multiple paid in 2020 can be compared against the population median for pharmacy transactions of similar size on our Pharmacy valuation hub.

Source

Data sourced from Press reporting. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology

Value your own pharmacy

Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.

Compare your business to the TarryTown ExpoCare Pharmacy acquisition.

Citation: ExitValue.ai. (2020). TarryTown ExpoCare Pharmacy acquired by Sheridan Capital. https://exitvalue.ai/deals/tarrytown-expocare-pharmacy-acquired-by-sheridan-capital-hc-2020-0134